CN101574396A - Compound preparation of fructus schisandrae and evening primrose CO* supercritical extract and preparation process - Google Patents
Compound preparation of fructus schisandrae and evening primrose CO* supercritical extract and preparation process Download PDFInfo
- Publication number
- CN101574396A CN101574396A CNA2009100671240A CN200910067124A CN101574396A CN 101574396 A CN101574396 A CN 101574396A CN A2009100671240 A CNA2009100671240 A CN A2009100671240A CN 200910067124 A CN200910067124 A CN 200910067124A CN 101574396 A CN101574396 A CN 101574396A
- Authority
- CN
- China
- Prior art keywords
- fructus schisandrae
- supercritical extract
- supercritical
- extract
- evening primrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 48
- 150000001875 compounds Chemical class 0.000 title claims abstract description 15
- 241000219925 Oenothera Species 0.000 title claims abstract description 13
- 235000004496 Oenothera biennis Nutrition 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 12
- 239000007901 soft capsule Substances 0.000 claims abstract description 9
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000012856 packing Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 229960001031 glucose Drugs 0.000 description 24
- 239000008103 glucose Substances 0.000 description 24
- 239000003814 drug Substances 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 4
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960004329 metformin hydrochloride Drugs 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a compound preparation of fructus schisandrae and evening primrose CO2 supercritical extract and a preparation process. The process is characterized by: grinding fruit of fructus schisandrae and seeds of evening primrose respectively to 40-60 meshes and putting the ground substances in a supercritical extraction device for extraction with the pressure being 35MPa, the temperature being 35-40 DEG C, and the speed being 2L/min; and subsequently obtaining the fructus schisandrae and evening primrose CO2 supercritical extract by extracting 2.5-3h; and according to parts by weight, putting 50-52 of the fructus schisandrae CO2 supercritical extract, 47-49 of the evening primrose CO2 supercritical extract and 1.0 of vitamin E in a mixture tank to be stirred, mixed evenly and delivered to a soft capsule packing machine for pelleting. The compound preparation is advanced in dosage form, guarantees lasting efficacy of effective ingredients, is low in the content of impurities and high in the content of the effective ingredients with active ingredients easily being absorbed, and is safer for eating and is a natural health food with CO2 used as extraction dissolvent and no residue of organic solvent.
Description
Technical field:
The present invention discloses a kind of Radix Schisandrae Bicoloris and Radix Oenotherae erythrosepalae CO
2The supercritical extract compound formulation is a kind of food with protection islet cells, auxiliary hyperglycemic function, the invention also discloses the preparation technology of above-mentioned compound formulation, belongs to health product technology field.
Background technology:
Fructus Schisandrae Chinensis is the fruit of magnoliaceae schisandra (FructusSchisandraeChinensis).Scientific research shows that Fructus Schisandrae Chinensis is different because of the place of production, north and south difference effect.The Fructus Schisandrae Sphenantherae color is red, can treat the cough due to wind and cold, and the Radix Schisandrae Bicoloris darkish complexion can be treated the body sweating due to debility and be hindered diseases such as essence more.That has now developed has Fructus Schisandrae Chinensis natural juice, Fructus Schisandrae Chinensis fruit juice, Fructus Schisandrae Chinensis fruit jelly, a Fructus Schisandrae Chinensis fruit wine etc., and common dosage forms medicinal or health product are syrup, electuary.Because the main functional component of Fructus Schisandrae Chinensis is the lignanoids material, mainly the method with decocting in water obtains, the extracts active ingredients of this extracting method is very incomplete, particularly the functional component in kernel and the shell can not fully be extracted, throw away with medicinal residues mostly, waste valuable drug resource, increased production cost of products.
The Radix Oenotherae erythrosepalae liposoluble constituent be applicable to have some setbacks menstrual period, climacteric discomfort, rheumatic arthritis and multiple degenerative joint, improve allergic constitution, the complication of pant, releive allergic eczema and antipruritic, confirmed fatigue, prevention fatty liver and liver cirrhosis, prevent diabetes, eliminate fat, cholesterol reducing, prevention of cardiac, preventing thrombosis, prevention of stroke etc. in advance.
Do not see the report of Fructus Schisandrae Chinensis and Radix Oenotherae erythrosepalae compound formulation by retrieval.
Summary of the invention:
The invention provides a kind of Radix Schisandrae Bicoloris and Radix Oenotherae erythrosepalae CO
2The supercritical extract compound formulation utilizes both synergism to protect islet cells and auxiliary blood sugar lowering.
Radix Schisandrae Bicoloris and Radix Oenotherae erythrosepalae CO have been the present invention further provides
2The preparation technology of supercritical extract compound formulation is suitable for suitability for industrialized production.
Radix Schisandrae Bicoloris of the present invention and Radix Oenotherae erythrosepalae CO
2The supercritical extract compound formulation is characterized in that being made up of following raw material by weight:
Fructus Schisandrae Chinensis CO
2Supercritical extract: 50～52
Radix Oenotherae erythrosepalae CO
2Supercritical extract: 47～49
Vitamin E: 1.0
The preparation of described compound formulation may further comprise the steps:
Fruit of Fructus Schisandrae Chinensis is crushed to 40 orders ~ 60 orders, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 40 ℃ of extraction temperature; 2L/min; Extract and obtained Fructus Schisandrae Chinensis CO in 3 hours
2Supercritical extract;
Evening primrose seed is crushed to 40 orders ~ 60 orders, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 35 ℃ of extraction temperature, 35 ℃ of separation temperatures; 2L/min; Extract and obtained Radix Oenotherae erythrosepalae CO in 2.5 hours
2Supercritical extract;
With Fructus Schisandrae Chinensis CO
2Supercritical extract, Radix Oenotherae erythrosepalae CO
2Supercritical extract and vitamin E are put into material-compound tank in proportion and are mixed, and send into soft capsule packer pelleting.
Be animal model with the genotype diabetes model below, prove the therapeutic effect of compound formulation of the present invention type ii diabetes.
1 material
1.1 animal
Genotype diabetes KK-A
yMice (male, body weight 25g ± 5g); The C57BL/6J mice (male, body weight 25g ± 5g), and all available from Chinese Academy of Medical Sciences's animal center, the quality certification: SYXK (army) 2002-042.
1.2 medicine
Metformin hydrochloride: Hebei Tiancheng Pharmaceutical Co., Ltd (former Cangzhou pharmaceutical factory);
Compound formulation of the present invention is provided by this laboratory.
2 experimental techniques
2.1 laboratory animal grouping and administration
KK-A
yMice high glucose and high fat forage feed, the C57BL/6J mice feeds and gets final product with normal diet.KK-A
yThe mice adaptability is raised and was surveyed blood glucose in the 3rd day, the 7th day, and the blood glucose value of twice mensuration basicly stable (fasting is 12 hours before surveying) is got the KK-A of blood glucose value greater than 11.1mol/L as a result
yMice is included experiment in.And with KK-A
yMice is divided into model group, high dose group (200mg/kg/d), middle dosage group (100mg/kg/d), low dose group (25mg/kg/d) and positive controls (metformin hydrochloride) (200mg/kg/d) at random by blood glucose value, and normal group and model group give the normal saline of equivalent 0.9%.Gastric infusion, successive administration take off neck and put to death after 35 days.
2.2 the mensuration of blood glucose value
Minute: diabetes heredity KK-A
yMice administration 35 days, during measure week about and respectively organize the mice fasting blood sugar.
Oral glucose tolerance test (OGTT): the phase is carried out an oral glucose tolerance test in test.Before the experiment, each organized the mice fasting 12 hours, surveyed blood glucose, as the 0min blood glucose value, irritated stomach then and gave respectively to organize mice G/W (2g/kg), timing, the blood glucose value when tail vein is got blood survey 30min, 60min, 120min.
The tail vein is got the mensuration of blood and blood glucose: survey the preceding fasting of blood glucose 12 hours, can't help water.The Mus tail exposes the tail venous engorgement with cotton ball soaked in alcohol wiping sterilization, cuts osculum with knife blade on vein, and outflow 1 is bled and dropped on the blood sugar test paper measurement window, writes down reading behind the 5s.When repeatedly measuring, otch is shifted to near-end from far-end.
3 results
5.2.2.1 the invention medicine is to diabetes KK-A
yThe influence of mouse blood sugar
Model group and normal group mouse blood sugar value keep more stable level; Along with the increase of administration natural law, administration group blood glucose value all becomes downward trend.Wherein, invention medicine high dose and middle dosage treatment group be the blood sugar lowering level obviously, and be remarkable with the model group comparing difference, has statistical significance (P＜0.01); But the blood glucose value level of low dose therapy group and model group comparing difference are not remarkable, not statistically significant (P＞0.05).Metformin hydrochloride group blood glucose value obviously descends, with remarkable (P＜0.001) (the seeing Table 1) of model group comparing difference.
Table 1 invention medicine is to diabetes KK-A
yThe influence of mouse blood sugar (n=10, x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group
5.2.2.2 oral glucose tolerance test (OGTT) result
After irritating stomach G/W 120min, invention medicine high dose group blood glucose value has obvious decline, and relatively there were significant differences with model group, has statistical significance (P＜0.01); Dosage group and low dose group blood glucose value also decrease in the invention medicine, and be more variant with model group, has statistical significance (P＜0.05); Three dosage groups of invention medicine with dosage be increased in 120min the time blood glucose value corresponding on a declining curve.Metformin hydrochloride group blood glucose value blood glucose value when 120min has obvious decline, and relatively there were significant differences with model group, has statistical significance (P＜0.01).Behind the injectable dextrose monohydrate, each administration group day part blood glucose value all is lower than model group (seeing Table 2).
Table 2 oral glucose tolerance experimental result (n=10, x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group
" clinical researches of Radix Oenotherae erythrosepalae oil breast treatment diabetes " (" Chinese endocrine metabolism magazine " // 1991 (7) 2:106-107) according to Jin Chaojun etc. show that Radix Oenotherae erythrosepalae oil breast blood sugar decreasing effect is: blood glucose value 10.4 ± 2.78 before the treatment, treatment back blood glucose value 7.68 ± 2.74 only reduces by 2.82.
Compound formulation of the present invention can reduce for blood glucose value and reaches 4.28.This is because Radix Oenotherae erythrosepalae blood sugar lowering and the synergistic result of Fructus Schisandrae oil protection islet cells.
Adopt soft capsule by totally enclosed form, content and air are completely cut off, avoid the destruction of light simultaneously, prevent the oxidation of content effective ingredient and lose effectiveness or contaminated, enhanced stability photoactive substance.Because the effective ingredient of soft capsule goods exists with liquid condition, dissolubility is good, has guaranteed your the high absorption rate to effective ingredient.
Adopt CO
2The supercritical extraction unit pressurization also contains a large amount of lignan components with containing a large amount of lipid components in extract of effective ingredient, particularly Fructus Schisandrae Chinensis kernel in the shell of Fructus Schisandrae Chinensis kind Renhe more in the shell, reduced the wasting of resources.CO
2Be extraction solvent extract at low temperature, guarantee that the thermal sensitivity functional component is not destroyed, organic solvent-free is residual, and is edible safer.
Good effect of the present invention is: prescription is based on pure Chinese medicinal preparation, utilizes the synergy curative effect type ii diabetes of Radix Oenotherae erythrosepalae oil and Fructus Schisandrae oil, and treating both the principal and secondary aspects of a disease is evident in efficacy, has no adverse reaction, and has no side effect.
The specific embodiment:
The present invention will be further described below in conjunction with embodiment:
Embodiment 1:
Fruit of Fructus Schisandrae Chinensis is crushed to 40 orders, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 40 ℃ of extraction temperature; 2L/min; Extract and obtained Fructus Schisandrae Chinensis CO in 3 hours
2Supercritical extract.
Evening primrose seed is crushed to 40 orders, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 35 ℃ of extraction temperature, 35 ℃ of separation temperatures; 2L/min; Extract and obtained Radix Oenotherae erythrosepalae CO in 2.5 hours
2Supercritical extract.
With Fructus Schisandrae Chinensis CO
2Supercritical extract is 52kg, evening primrose seed CO
2Supercritical extract is that 47kg and vitamin E are that 1.0kg puts into material-compound tank and mixes, and sends into soft capsule packer pelleting.
Embodiment 2:
Fruit of Fructus Schisandrae Chinensis is crushed to 60 orders, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 40 ℃ of extraction temperature; 2L/min; Extract and obtained Fructus Schisandrae Chinensis CO in 3 hours
2Supercritical extract.
Evening primrose seed is crushed to 60 orders, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 35 ℃ of extraction temperature, 35 ℃ of separation temperatures; 2L/min; Extract and obtained Radix Oenotherae erythrosepalae CO in 2.5 hours
2Supercritical extract.
With Fructus Schisandrae Chinensis CO
2Supercritical extract is 51kg, evening primrose seed CO
2Supercritical extract is that 48kg and vitamin E are that 1.0kg puts into material-compound tank and mixes, and sends into soft capsule packer pelleting.
Embodiment 3:
Fruit of Fructus Schisandrae Chinensis is crushed to 50 orders, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 40 ℃ of extraction temperature; 2L/min; Extract and obtained Fructus Schisandrae Chinensis CO in 3 hours
2Supercritical extract.
Evening primrose seed is crushed to 50 orders, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 35 ℃ of extraction temperature, 35 ℃ of separation temperatures; 2L/min; Extract and obtained Radix Oenotherae erythrosepalae CO in 2.5 hours
2Supercritical extract.
With Fructus Schisandrae Chinensis CO
2Supercritical extract is 50kg, evening primrose seed CO
2Supercritical extract is that 49kg and vitamin E are that 1.0kg puts into material-compound tank and mixes, and sends into soft capsule packer pelleting.
Claims (2)
1, a kind of Radix Schisandrae Bicoloris and Radix Oenotherae erythrosepalae CO
2The supercritical extract compound formulation is characterized in that being made up of following raw material by weight:
Fructus Schisandrae Chinensis CO
2Supercritical extract: 50～52
Radix Oenotherae erythrosepalae CO
2Supercritical extract: 47～49
Vitamin E: 1.0.
2, the described preparation of soft capsule technology of claim 1 may further comprise the steps:
Fruit of Fructus Schisandrae Chinensis is crushed to 40 orders-60 order, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 40 ℃ of extraction temperature; 2L/min; Extract and obtained Fructus Schisandrae Chinensis CO in 3 hours
2Supercritical extract;
Evening primrose seed is crushed to 40 orders-60 order, puts into CO
2In the supercritical extraction unit, with 35MPa pressure; 35 ℃ of extraction temperature, 35 ℃ of separation temperatures; 2L/min; Extract and obtained Radix Oenotherae erythrosepalae CO in 2.5 hours
2Supercritical extract;
With Fructus Schisandrae Chinensis CO
2Supercritical extract, Radix Oenotherae erythrosepalae CO
2Supercritical extract and vitamin E are put into material-compound tank in proportion and are mixed, and send into soft capsule packer pelleting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100671240A CN101574396A (en) | 2009-06-17 | 2009-06-17 | Compound preparation of fructus schisandrae and evening primrose CO* supercritical extract and preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100671240A CN101574396A (en) | 2009-06-17 | 2009-06-17 | Compound preparation of fructus schisandrae and evening primrose CO* supercritical extract and preparation process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101574396A true CN101574396A (en) | 2009-11-11 |
Family
ID=41269556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009100671240A Pending CN101574396A (en) | 2009-06-17 | 2009-06-17 | Compound preparation of fructus schisandrae and evening primrose CO* supercritical extract and preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101574396A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102845750A (en) * | 2012-09-19 | 2013-01-02 | 无锡市天赐康生物科技有限公司 | Hypoglycemic health food and preparation method thereof |
| CN102885300A (en) * | 2012-09-19 | 2013-01-23 | 无锡市天赐康生物科技有限公司 | Health-care food with blood sugar reducing effect and preparation method thereof |
| WO2022085602A1 (en) * | 2020-10-20 | 2022-04-28 | サントリーホールディングス株式会社 | Composition for tgr5 activation |
-
2009
- 2009-06-17 CN CNA2009100671240A patent/CN101574396A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102845750A (en) * | 2012-09-19 | 2013-01-02 | 无锡市天赐康生物科技有限公司 | Hypoglycemic health food and preparation method thereof |
| CN102885300A (en) * | 2012-09-19 | 2013-01-23 | 无锡市天赐康生物科技有限公司 | Health-care food with blood sugar reducing effect and preparation method thereof |
| WO2022085602A1 (en) * | 2020-10-20 | 2022-04-28 | サントリーホールディングス株式会社 | Composition for tgr5 activation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101601080B1 (en) | Composition comprising curcuma longa extract together with curcuma zedoaria extract | |
| EP3193898B1 (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| CN1853682A (en) | Plant based dietary supplement for improving the duration and quality of sleep | |
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| CN1840166A (en) | Wendan decoction modern traditional Chinese medicine oral preparation and production method thereof | |
| CN101708241B (en) | Medicinal composition for eliminating dampness and relieving itching | |
| CN113349381A (en) | Food composition capable of relieving depression and preparation method thereof | |
| CN1143681C (en) | Medicinal composition for diabetes | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| KR101771090B1 (en) | Composition for body temperature rise with medicinal herbs classified as a food ingredient and Manufacturing method thereof | |
| CN101574396A (en) | Compound preparation of fructus schisandrae and evening primrose CO* supercritical extract and preparation process | |
| RU2351354C1 (en) | Medication for treatment and prevention of thyroid gland diseases | |
| CN104306554B (en) | A kind of food, health products or pharmaceutical composition for treating gastric ulcer | |
| CN103251698A (en) | A kudzu root drinking liquid with anti-alcoholic, liver-protecting and stomach-protecting effects and its preparation method | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| CN101810649A (en) | Method for preparing pine needle distilled and concentrated solution | |
| KR101808944B1 (en) | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract | |
| CN110063977B (en) | Radix codonopsis and sea buckthorn composite electuary and application thereof | |
| CN102614253B (en) | Composition for nourishing and protecting liver and application of composition | |
| KR101423316B1 (en) | Composition for prevention or treatment of osteoarthritis including extracts of Phyllanthus tenellus | |
| CN110585254A (en) | Preparation method of original ecological ginseng chewable tablets and granules | |
| CN101744991B (en) | Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| RU2114628C1 (en) | Component composition "adaptovit" showing antihypoxic effect | |
| CN110960605A (en) | Eye-protecting traditional Chinese medicine composition | |
| CN104547022A (en) | Traditional Chinese medicinal composition capable of clearing heat, moistening lung, relieving sore throat and detoxifying |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20091111 |